Antibodies News and Research

RSS

Theraclone Sciences commences TCN-202 Phase 1 trial in CMV infection

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today first dosing of subjects in a Phase 1 clinical trial of TCN-202, a broadly protective, fully human monoclonal antibody in development for the treatment of human cytomegalovirus (CMV) infection.

15 Jun 2012

FDA approves Menhibrix for vaccination against meningococcal and Hib diseases

The U.S. Food and Drug Administration today approved Menhibrix, a combination vaccine for infants and children ages 6 weeks through 18 months, for prevention of invasive disease caused by Neisseria meningitidis serogroups C and Yand Haemophilus influenzae type b.

15 Jun 2012

Hay fever vaccine shows efficacy in phase IIa trial

A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.

14 Jun 2012

Laparoscopy technique lights up invisible metastases

Fluorescence laparoscopy could be the way forward for cancer surgery and staging, say researchers writing in the Archives of Surgery.

14 Jun 2012

Reovirus can trick the body's defenses to reach and kill cancer cells

Scientists have shown how a promising viral therapy that delivers a double blow to cancer can sneak up on tumors undetected by hitching a ride on blood cells.

14 Jun 2012

Cancers often recur after treatment with single drugs that “target” tumor cells’ genetic pathways

Targeted cancer cell therapies using man-made proteins dramatically shrink many tumors in the first few months of treatment, but new research from Johns Hopkins scientists finds why the cells all too often become resistant, the treatment stops working, and the disease returns.

14 Jun 2012

Transgenic mosquitoes can control malaria

Mosquitoes bred to be unable to infect people with the malaria parasite are an attractive approach to helping curb one of the world's most pressing public health issues, according to UC Irvine scientists.

13 Jun 2012

Igenica raises $33M in Series C round of funding

Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of first-in-class antibodies, today announced that it has raised $33 million in a Series C round of funding.

12 Jun 2012

NMDA antibodies increased in mania patients

Patients with bipolar disorder show increased levels of antibodies to the NR2 subunits of the N-methyl-D-aspartate receptor during periods of acute mania, researchers report.

12 Jun 2012

CRT, BioInvent partner to identify new therapeutic antibodies in oncology

BioInvent International AB and Cancer Research Technology Ltd (CRT), the commercial arm of Cancer Research UK, announced today that they have entered a collaboration with Queen Mary, University of London, to identify new therapeutic antibodies in oncology.

12 Jun 2012

Scientists image structure of bacterium protein coat

Bacteria are omnipresent - in the water, the air and the soil, as well as in plants, animals and even people. We tend to think of bacteria as pathogenic, causing disease. We associate them with intestinal upsets and throat infections, pneumonia and blood poisoning.

11 Jun 2012

CLC bio implements specialized antibody engineering and selection module for Crucell

Today CLC bio announced the completion and final implementation of a specialized antibody engineering and selection module for Crucell, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, that integrates with CLC bio's bioinformatics platform.

11 Jun 2012

U of M, AbSorber to evaluate XM-ONE in their Living Donor program

The transplantation unit at Jackson Memorial Hospital and the University of Miami, FL, USA has entered into a research project with the Allenex group company AbSorber. The project is a pilot study evaluating the endothelial cell cross match XM-ONE in their Living Donor program.

8 Jun 2012

Clinical study shows positive effects of CAD106 vaccine against AD

A study led by Karolinska Institutet in Sweden reports for the first time the positive effects of an active vaccine against Alzheimer's disease. The new vaccine, CAD106, can prove a breakthrough in the search for a cure for this seriously debilitating dementia disease. The study is published in the distinguished scientific journal Lancet Neurology.

7 Jun 2012

Paper spotlights unique developmental strategy undertaken by all mammals

Ask the average person the street how the brain develops, and they'll likely tell you that the brain's wiring is built as newborns first begin to experience the world. With more experience, those connections are strengthened, and new branches are built as they learn and grow. A new study conducted in a Harvard lab, however, suggests that just the opposite is true.

7 Jun 2012

Omentum appears to play an important role in regulating the immune system

A fatty membrane in the belly called the omentum has until recently been considered somewhat like the appendix -- it didn't seem to serve much purpose. But Loyola University Chicago Stritch School of Medicine researchers have found that the omentum appears to play an important role in regulating the immune system.

7 Jun 2012

Pioneering new test can quickly diagnose coeliac disease

Coeliac disease affects millions of people worldwide, but many sufferers are not aware they have the condition or may have been misdiagnosed with other illnesses. A pioneering new test developed with EU-funding should soon be available in hospitals, offering an accurate, quick, cost-effective diagnosis and monitoring solution.

6 Jun 2012

New PD-1 blocking antibody shows promise against advanced kidney cancer

An antibody that helps a person's own immune system battle cancer cells shows increasing promise in reducing tumors in patients with advanced kidney cancer, according to researchers at Beth Israel Deaconess Medical Center.

5 Jun 2012

Parkinson’s vaccine: worldwide first clinical trial begins

The worldwide first clinical trial for the development of a Parkinson´s vaccine has now been started by AFFiRiS AG.

5 Jun 2012

High levels of antibody molecule linked to increased rates of death from all diseases

Mayo Clinic researchers have identified an immune system deficiency whose presence shows someone is up to four times likelier to die than a person without it. The glitch involves an antibody molecule called a free light chain; people whose immune systems produce too much of the molecule are far more likely to die of a life-threatening illness such as cancer, diabetes and cardiac and respiratory disease than those whose bodies make normal levels. The study is published in the June issue of Mayo Clinic Proceedings.

4 Jun 2012